Mytos is building the first robust, high-throughput platform for the automated manufacture of any human cell types. Testing on cell lines is core to the development of new therapies. Mytos’s platform enables Pharma & Biotech research teams to scale cell production in house, dramatically lowering costs and increasing productivity.
IQ Capital first invested in Mytos at Series A in 2023.